FOXA1 and breast cancer: Finally, we found that expression for the chromatin factor ANP32E was anti-correlated with tumor progression and with accessibility at FOXA1 binding sites among group 2 and 3 tumors, suggestive of a novel mechanism by which FOXA1 activity may be regulated in breast cancer tumors.